RAD1 Protein (Transcript Variant 1) (Myc-DYKDDDDK Tag)
-
- Target See all RAD1 Proteins
- RAD1 (Cell Cycle Checkpoint Protein RAD1 (RAD1))
- Protein Type
- Recombinant
- Protein Characteristics
- Transcript Variant 1
-
Origin
- Human
-
Source
- HEK-293 Cells
- Purification tag / Conjugate
- This RAD1 protein is labelled with Myc-DYKDDDDK Tag.
- Application
- Antibody Production (AbP), Standard (STD)
- Characteristics
-
- Recombinant human RAD1 (transcript variant 1) protein expressed in HEK293 cells.
- Produced with end-sequenced ORF clone
- Purity
- > 80 % as determined by SDS-PAGE and Coomassie blue staining
- Top Product
- Discover our top product RAD1 Protein
-
-
- Application Notes
-
Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays - Comment
-
The tag is located at the C-terminal.
- Restrictions
- For Research Use only
-
- Concentration
- 50 μg/mL
- Buffer
- 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
- Storage
- -80 °C
- Storage Comment
- Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.
-
- Target
- RAD1 (Cell Cycle Checkpoint Protein RAD1 (RAD1))
- Alternative Name
- Rad1 (RAD1 Products)
- Synonyms
- HRAD1 Protein, REC1 Protein, zgc:56502 Protein, zgc:77779 Protein, RAD1 Protein, xrad1 Protein, DKFZp459H1127 Protein, RAD1 checkpoint DNA exonuclease Protein, RAD1 homolog (S. pombe) Protein, RAD1 Protein, Rad1 Protein, rad1 Protein
- Background
- This gene encodes a component of a heterotrimeric cell cycle checkpoint complex, known as the 9-1-1 complex, that is activated to stop cell cycle progression in response to DNA damage or incomplete DNA replication. The 9-1-1 complex is recruited by RAD17 to affected sites where it may attract specialized DNA polymerases and other DNA repair effectors. Alternatively spliced transcript variants of this gene have been described.
- Molecular Weight
- 31.6 kDa
- NCBI Accession
- NP_002844
- Pathways
- M Phase
-